PMCC PMCC

Search tips
Search criteria

Advanced
Results 1-4 (4)
 

Clipboard (0)
None
Journals
Authors
more »
Year of Publication
Document Types
1.  Tumor-Specific Systemic Treatment in Advanced Breast Cancer – How Long does it Make Sense? 
Breast Care  2011;6(1):35-41.
Summary
Metastatic breast cancer (MBC) is a chronic and incurable disease which can be kept steady for a long time with continuous oncologic therapy. There are various treatment options. Disease-free as well as overall survival were prolonged in many pharmaceutical studies. The therapist focuses on these oncologic parameters as well as the patient's quality of life. One central point of the communication between doctor and patient is the prediction by the medical team of how long to continue oncologic therapy and when to start palliative medicine in terms of best palliative care. Treatment options currently available for MBC as well as the importance of this difficult communication between the involved parties are pointed out. The end of tumor-specific oncologic therapy does not necessarily mean the end of therapeutic measures for the individual patient.
doi:10.1159/000324455
PMCID: PMC3083269  PMID: 21547024
Metastatic breast cancer; Terminal illness; Palliative care; Communication; Patient-centered care
2.  Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer 
Breast Care  2010;5(Suppl 1):13-15.
Summary
In women with estrogen receptor(ER)- and ErbB2 (HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance. As such, co-targeting ErbB1 and ErbB2 with lapatinib in combination with hormonal therapy is an attractive approach to enhance the efficacy of either tamoxifen or estrogen deprivation. As demonstrated in the EGF30008 trial, a combined targeted strategy with letrozole and lapatinib significantly increased progression-free survival and clinical benefit rates in patients with metastatic breast cancer that co-expresses ER and ErbB2. Therefore, women who are not in an acutely life-threatening situation should be considered for upfront treatment with hormonal therapy (e.g. aromatase inhibitors) in combination with an anti-ErbB2 therapy.
doi:10.1159/000285775
PMCID: PMC2931095  PMID: 20847831
ErbB2-positive breast cancer; Hormone receptors; ErbB2/ER pathway crosstalk; Endocrine resistance; EGF30008 trial
3.  News from the San Antonio Breast Cancer Symposium 2009 
Breast Care  2010;5(1):38-43.
doi:10.1159/000283284
PMCID: PMC3357166  PMID: 22649330
4.  Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens? 
Breast Care  2008;3(4):244-250.
Summary
Breast cancer-associated mortality has been significantly reduced since the 1990s, mainly because of early diagnosis and systemic therapeutic interventions. All three therapy components – cytostatic therapy, endocrine therapy and targeted antibody therapy – are at present necessary tools for the curative treatment of primary breast cancer. This article reviews the evidence base for the use of various chemotherapy schedules in patients with primary, node-positive breast cancer, including schedules in combination with targeted HER2/neu therapy.
doi:10.1159/000149099
PMCID: PMC2974979  PMID: 21076604
Chemotherapy; Prognosis; Recurrence; Breast cancer; Controversies; Taxanes; Anthracyclines; Trastuzumab

Results 1-4 (4)